Hologic Showcases New Breast Surgery Franchise at 20th Annual Meeting of The American Society of Breast Surgeons

Hologic_Main_Logo_Small_White_cropped-1

Breast health leader will highlight expanding portfolio for breast
conserving surgery

MARLBOROUGH, Mass.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/ASBS?src=hash” target=”_blank”gt;#ASBSlt;/agt;–Hologic, Inc. (Nasdaq: HOLX) will showcase its growing breast surgery
franchise, which includes products such as the new Trident® HD specimen
radiography system, LOCalizer wire-free guidance system and
the BioZorb® marker, in Booth #103 at the 20th
Annual Meeting of The American Society of Breast Surgeons (ASBS) in
Dallas from April 30 to May 5.

The pioneer behind the Genius 3D Mammography
exam, Hologic has recently expanded its product portfolio significantly
through insight-driven innovation and strategic acquisitions to address
the entire clinical continuum of breast cancer diagnosis and care. From
digital specimen radiography and stereotactic breast biopsy systems, to
breast biopsy markers and surgical guidance systems – Hologic’s
comprehensive suite of products is designed to meet the unmet and
changing needs of radiologists, pathologists and breast surgeons.

“ASBS marks an exciting milestone this year as we debut our newly
expanded portfolio of breast conserving surgery solutions,” said Pete
Valenti, Hologic’s Division President, Breast and Skeletal Health
Solutions. “We look forward to building upon our relationships with this
community of leading breast surgeons and showcasing our growing suite of
products designed to improve cancer detection, patient satisfaction and
comfort, and facility workflow.”

A sampling of the products on display in the Hologic booth includes:

  • The Trident®
    HD specimen radiography system
    , a next-generation solution
    that delivers enhanced image quality, improved workflow and instant
    sample verification during breast-conserving surgeries and
    stereotactic breast biopsies.1 The system, which recently
    received FDA clearance in the U.S. and a CE Mark in Europe, uses
    amorphous selenium direct capture imaging – the same detector
    technology used in Hologic’s 3Dimensions™ mammography system – to
    generate crisp, clear, high-resolution images. The system also
    features a bigger detector that allows for complete imaging of larger
    breast surgical specimens, along with a wide range of surgical and
    biopsy samples.2
  • The LOCalizer
    wire-free guidance system
    , which is designed to enable
    precision and ease of use for breast surgery guidance. The LOCalizer
    tag is designed to replace traditional wire-guided methods, helping
    provide increased comfort and convenience for patients and their
    healthcare teams. Additionally, the Tag is designed to be implanted
    into the breast any time prior to the surgery, providing increased
    flexibility for patients and providers. A recent study has shown that
    the LOCalizer tag may be able to reduce positive margin rates with
    lumpectomy due to the unique feature of reading distance from the tag.3
  • The BioZorb®
    3D bioabsorbable marker
    , an implantable three-dimensional
    marker that potentially enables a more targeted radiation therapy and
    helps clinicians overcome challenges in breast conserving surgery or
    lumpectomy. When used to mark the surgical site, BioZorb has been
    shown to yield good to excellent cosmetic outcomes for at least two
    years post-surgery and result in minimal scarring on mammography after
    breast conserving surgery.4,5 Additionally, the marker has
    been shown to improve accuracy in setup and boost targeting as
    reported by 96 percent of radiation oncologists.6
  • The TruNode®
    wireless gamma probe
    , a sterile, single-use device for common,
    radio-guided surgical procedures that senses hotspots using an
    innovative detector and heuristic audio feedback technology. The
    TruNode probe is designed to perform less invasively, and may reduce
    infection risk from reprocessing due to its sterile, single-use
    performance.

Hologic will also host a breakfast symposium, BioZorb® and a New Way
to 5-day radiation
, featuring Cary Kaufman, MD, FACS and Valerie
Gorman, MD, FACS on Saturday, May 4 from 6:30 – 7:45am. Additional hands-on
workshops hosted by Hologic will cover topics such as stereotactic
breast biopsy, oncoplastic skills and portable breast ultrasound.

The Genius3D Mammographyexam (also known as
the Genius exam) is only available on a Hologic®3D
Mammography™system. It consists of a 2D and 3Dimage
set, where the 2D image can be either an acquired 2D image or a 2D image
generated from the 3Dimage set. There are more than 6,000
Hologic 3D Mammography systems in use in the U.S. alone, so
women have convenient access to the Genius exam. To learn more about the
Genius exam, visit http://www.Genius3DNearMe.com.

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily
focused on improving women’s health and well-being through early
detection and treatment. For more information on Hologic, visit www.hologic.com.

Hologic, 3D, 3D Mammography, 3Dimensions, BioZorb, Genius, The Science
of Sure, Trident and TruNode are trademarks and/or registered trademarks
of Hologic, Inc., and/or its subsidiaries in the United States and/or
other countries. Hologic is an exclusive distributor and licensee of the
LOCalizer product and trademark, which is manufactured by Health Beacons.

Forward-Looking Statements

This news release may contain forward-looking information that involves
risks and uncertainties, including statements about the use of Hologic
products. There can be no assurance these products will achieve the
benefits described herein or that such benefits will be replicated in
any particular manner with respect to an individual patient, as the
actual effect of the use of the products can only be determined on a
case-by-case basis. In addition, there can be no assurance that these
products will be commercially successful or achieve any expected level
of sales. Hologic expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any such statements
presented herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such data or statements
are based.

This information is not intended as a product solicitation or promotion
where such activities are prohibited. For specific information on what
products are available for sale in a particular country, please contact
a local Hologic sales representative or write to womenshealth@hologic.com.

SOURCE: Hologic, Inc.

1 Wilson A. Trident 2.0 QUAL Qualitative Findings. Explore
and identify the ideal breast biopsy verification system from the OR.
Kadence International. July 2016.
2 Compared to original
Trident system
3 N = 50 patient, single arm pilot study.
DiNome M et al. Microchipping the breast: an effective new technology
for localizing non-palpable breast lesions for surgery. Poster
presentation, Society of Surgical Oncology annual meeting, Mar 27-30,
2019.
4 Kaufman, et al. Oncoplastic
Surgery with the 3-D Tissue Implant Maintains Post-Lumpectomy Breast
Contour
. Poster presented at the American Society of Breast Surgeons
18th Annual Meeting, May 2-5, 2018.
5 Kaufman CS, et al. Registry
Study of 337 Bio-Absorbable 3-D Implants Marking Lumpectomy Cavity
Benefit Cosmesis While Targeting Radiation
. Poster presented at the
Society of Surgical Oncology Annual Cancer Conference March 15-17, 2017.
6
Harms S, et al. Mammographic
imaging after partial breast reconstruction: Impact of a bioabsorbable
breast implant.
 J Clin Oncol 33, 2015 (suppl 28S; abstr 111)

Contacts

Media Contact:
Jane Mazur
508.263.8764
(direct)
585.355.5978 (mobile)
jane.mazur@hologic.com

Investor Contact:
Michael Watts
858.410.8588
michael.watts@hologic.com